Abstract
Purpose
Current guidelines recommend withholding sodium–glucose cotransporter 2 inhibitors perioperatively due to concerns of euglycaemic diabetic ketoacidosis. However, such guidelines are largely based on case reports and small case series, many extrapolated from non-surgical patients. The aim was to investigate whether withholding sodium–glucose cotransporter 2 inhibitors as per current perioperative guidelines was associated with a reduction in serious adverse events, including euglycaemic diabetic ketoacidosis.
Methods
Instances of perioperative management of sodium–glucose cotransporter 2 inhibitors, over a four-year period were classified into two categories: those where sodium–glucose cotransporter 2 inhibitors were withheld as per guidelines and those where sodium–glucose cotransporter 2 inhibitors were administered in the perioperative period. The primary outcome was ‘total major perioperative complications’: a composite of serious adverse events including euglycaemic diabetic ketoacidosis, diabetic ketoacidosis, acute kidney injury, urosepsis and death.
Results
Eighty-two instances in 64 patients were included. Withholding sodium–glucose cotransporter 2 inhibitors was associated with an increased incidence of total major perioperative complications and poorer glycaemic control postoperatively. Multivariable logistic regression analysis revealed that withholding sodium–glucose cotransporter 2 inhibitors perioperatively (OR = 13.15; 95% CI = 1.8–138.9) and preoperative urea (OR 1.85 (95% CI = 1.17–3.43) were independently associated with an increase in total major postoperative complications.
Conclusion
Withholding sodium–glucose cotransporter 2 inhibitors as per current guidelines was associated with an increase in postoperative complications and reduced glycaemic control.
Keywords
Get full access to this article
View all access options for this article.